Less, but better: A simplified design for T cell redirection and conditional payload delivery
- PMID: 36513045
- DOI: 10.1016/j.ccell.2022.11.012
Less, but better: A simplified design for T cell redirection and conditional payload delivery
Abstract
Combining immune receptor engineering with conditional expression of accessory molecules holds great promise for advancing the field of cell-based immunotherapies. In this issue of Cancer Cell, Smole et al. introduce a modular single vector system to simultaneously redirect T cell specificity toward cancer antigens while achieving activation-gated delivery of customizable payloads.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.A.K. is on the scientific and/or clinical advisory boards for Achilles Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Catamaran Bio, Obsidian Therapeutics, and T-knife; has consulted for Bristol Myers Squibb, Decheng Capital, PACT Pharma, and Roche/Genentech; and has patents broadly related to cell and gene therapy outside the scope of this work.
Comment on
-
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety.Cancer Cell. 2022 Dec 12;40(12):1470-1487.e7. doi: 10.1016/j.ccell.2022.11.006. Cancer Cell. 2022. PMID: 36513049 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical